Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.
Rik J VerheijdenAnne M MayChristian U BlankMaureen J B AartsFranchette W P J van den BerkmortelAlfonsus J M van den EertweghJan Willem B de GrootMarye J Boers-SonderenJacobus J M van der HoevenGeke A HospersDjura PiersmaRozemarijn S van RijnAlbert J Ten TijeAstrid A M van der VeldtGerard VreugdenhilMichiel C T van ZeijlMichel W J M WoutersJohn B A G HaanenEllen H W KapiteijnKarlijn P M SuijkerbuijkPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Patients experiencing severe ICI toxicity have a prolonged OS. However, this survival advantage is abrogated when anti-TNF is administered for steroid-refractory toxicity. Further prospective studies are needed to assess the effect of different immunosuppressive regimens on checkpoint inhibitor efficacy.See related commentary by Weber and Postow, p. 2085.